Vabysmo 6 mg/0,05 ml, Injektionslösung

7680683950019 CH-68395 Injektionslösung
Vabysmo 6 mg/0,05 ml, Injektionslösung
Vabysmo 6 mg/0,05 ml, Injektionslösung
1 / 2
google

Article details

Package size
1
Selling units
1
Measure
Durchstechflasche(n)
Galenic form
Injektionslösung
Galenic group
Injektion/Infusion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
12/06/2025
Summary of Product Characteristics
Français
12/06/2025
Summary of Product Characteristics
Italien
12/06/2025

Detailed composition

Substance Quantity Type Category
(N/A)
6.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
0.028 MG Substance HBESI
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK

Reimbursement information

Public price
CHF 920.00
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/08/2022

Authorization holder

Roche Pharma (Schweiz) AG

4058 Basel

Authorization information

Swissmedic authorization number
68395
Drug name
Vabysmo, Injektionslösung
Galenic form
LSINJ
ATC Code
S01LA09
Authorization status
Z
Dispensing category
B
First authorization
25/05/2022
Authorization expiration date
24/05/2027
IT Number
11.99.0.
Domain
Human medicine
Field of application
Neovaskuläre altersbedingte Makuladegeneration und diabetisches Makulaödem; Makulaödem infolge eines retinalen Venenverschlusses (BRVO und CRVO)

Package details

Description (FR)
VABYSMO sol inj 6 mg/0.05 ml flac 0.24 ml
Description (DE)
VABYSMO Inj Lös 6 mg/0.05 ml Durchstf 0.24 ml
Market launch
25/05/2022
Narcotic (BTM)
No